Zhengchuan Pharmapack(SH:603976)2026-01-29 09:05Financial Performance Forecast - The company expects a net profit attributable to shareholders for 2025 to be between 18 million and 24 million yuan, a decrease of 29.25 million to 35.25 million yuan compared to the previous year, representing a decline of 54.93% to 66.20%[3]. - The projected net profit attributable to shareholders after deducting non-recurring gains and losses is expected to be between 11 million and 16 million yuan, down by 33.29 million to 38.29 million yuan year-on-year, reflecting a decrease of 67.54% to 77.69%[5]. - The total profit for the previous year was 60.21 million yuan, with a net profit attributable to shareholders of 53.25 million yuan and a net profit after deducting non-recurring gains and losses of 49.29 million yuan[6]. Factors Affecting Performance - The decline in performance is attributed to multiple factors including the deepening of pharmaceutical procurement policies, medical insurance payment reforms, and intensified market competition, leading to fluctuations in downstream customer demand and a decrease in product prices and sales volume[7]. Earnings Forecast Reliability - The earnings forecast is based on preliminary calculations by the company's finance department and has not been audited by registered accountants[8]. - The company emphasizes that there are no significant uncertainties affecting the accuracy of this earnings forecast[8]. - Investors are advised to pay attention to investment risks as the data provided is preliminary and the final financial figures will be disclosed in the official 2025 annual report[9].